Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-03-30
1999-10-26
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3800
Patent
active
059728833
ABSTRACT:
A method for the treatment of neurodegenerative diseases comprising administering to a patient in need of such treatment a therapeutically effective amount of a peptide compound selected from the group consisting of:
REFERENCES:
patent: 4605641 (1986-08-01), Bolin et al.
patent: 5147855 (1992-09-01), Gozes et al.
Gordon et al. Neuroscience Letters. 199, 1-4, 1995.
Masliah et al. Experimental Neurology, 136, 107-122, 1995.
Masliah et al. Brian Research, 751, 307-314, 1997.
Oitzl et al. Brain Research, 752, 189-196, 1997.
Morris et al, Neurology,, 39, 1159-1165, 1989.
Raffaele et al, Psychopharmacol. 27, 315-319, 1991.
Gregoriadis, G. et al. 1993. T. Biotech. 11: 440-442.
Koutouzis, T.K. et al. 1994. Crit. Review Microbiol. 8(3): 125-162.
Brenneman, D.E. et al. 1985. Peptides 6:35-39.
Gozes, I et al. 1992. J. Clin. Invest. 90:810-814.
The Merck Index, 1976 pp. 223, 1136-1137. Merck & Co. Inc., Rahway, N.J.
Gozes et al., VIP: Molecular Biology and Neurobiological Function Molecular Neurobiology, vol. 3, pp. 201-236, 1989.
Hill et al, Vasoactive Intestinal Peptide Antagonist Retards the Development of Neonatal Behaviors in the Rat, Peptides, vol. 12, pp. 187-192, 1991.
Glowa et al, Learning Impairment Following Intracerebral Administration of the HIV Envelope protein gp120 or a VIP Antagonist, Brain Research, vol. 570, pp. 49-53, 1992.
Rossor et al, Reduced Cortical Choline Acetyltransferase Activity in Senile Dementia of Alzheimer type is not Accompanied by Changes in Vasoactive Intestinal Polypeptide, Brain Research, vol. 201, pp. 249-253, 1980.
Bouras et al, Neuropeptides in Alzheimer's Disease: A Review and Morphological Results, Prog. Neuro-Psychopharmacol & Biol. Psychiatry, vol. 10, pp. 271-286, 1986.
Sunderland et al, Reduced Cerebrospinal Fluid Dynorphin A1-8 in Alzheimer's Disease, Biol. Psychiatry, vol. 30, pp. 81-87, 1991.
Wikkelso et al, Neuropeptides in Cerebrospinal Fluid in Normal-Pressure Hydrocephalus and Dementia, Eur. Neurol, vol. 31, pp. 88-93, 1991.
Arai et al, Somatostatin and Vasoactive Intestinal Polypeptide in Postmortem Brains from Patients with Alzheimer-Type Dementia, Neurosci. Lett., vol. 52, pp. 73-78, 1984.
Brenneman et al, Nonneuronal Cells Mediate Neurotrophic Action of Vasoactive Intestinal Peptide, The Journal of Cell Biology, vol. 104, pp. 1603-1610, Jun. 1987.
McCarthy et al, Preparation of Separate Astroglial and Oligodendroglial Cell Cultures From Rat Cerebral Tissue, J. Cell Biology, vol. 85, pp. 890-902, Jun. 1980.
Evans et al, Regulation of Cyclic AMP Accumulation by Peptide Hormone Receptors in Immunocytochemically Defined Astroglial Cells, Journal of Neurochemistry, vol. 43, pp. 131-138, 1984.
Gozes et al, Vasoactive Intestinal Peptide Potentiates Sexual Behavior: Inhibition by Novel Antagonist, Endocrinology, vol. vol. 125, No. 6, pp. 2945-2949, 1989.
Gozes et al, An Antagonist to Vasoactive Intestinal Peptide Affects Cellular Functions in the Central Nervous System, The Journal of Pharmacology and Experimental Therapeutics, vol. 257, No. 3, pp. 959-966, 1991.
Gozes et al, A VIP Antagonist Distinguishes VIP Receptors on Spinal Cord Cells and Lymphocytes, Brain Research, vol. 540, pp. 319-321, 1991.
Fisher et al, (+)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats, Neurosci Letters, vol. 102, pp. 325-331, 1989.
Chiou, Systemic Delivery of Polypeptide Drugs Through Ocular Route, Annu. Rev. Pharmacol. Toxicol., vol. 31, pp. 457-467, 1991.
Forsythe et al, Slow Excitatory Postsynaptic Currents Medisted by N-Methyl- D-Aspartate Receptors on Cultured Mouse Central Neurones, Journal of Physiology, vol. 396, pp. 515-533, 1988.
Pike et al, Neurodegeneration Induced by B-Amyloid Peptides in vitro: The Role of Peptide Assembly State, The Journal of Neuroscience, vol. 13, No. 4, pp. 1676-1687, Apr. 1993.
Goldman et al, (1991), In "Principles of Newal Science", E.R. Kandel et al, eds., Elsevier Science Publishing Co., Inc., N.Y., pp. 974-983.
Stryer, (1988), "Biochemistry", W.H. Freeman and Co., N.Y., pp. 16-20 and 470-471.
"The Menck Index", M. Windholz et al, eds., (1976), Mench and Co., Inc., Rahway, N.J., pp. 223 and 1136-1137.
Gozes et al, (1994), Endocrinology, 134(5): 2121-2125.
Gozes et al, (1993), J. Molec. Neurosci., 4(3): 185-193.
Fridkin Matityahu
Gozes Illana
Hutzell Paula K.
Ramot University Authority for Applied Research and Industrial
Sun-Hoffman Lin
Yeda Research and Development Co. Ltd.
LandOfFree
Method for the treatment of neurodegenerative diseases by admini does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of neurodegenerative diseases by admini, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of neurodegenerative diseases by admini will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764434